HRT Financial’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.25M Sell
40,504
-29,626
-42% -$1.59M 0.01% 1542
2025
Q4
$3.4M Buy
70,130
+45,105
+180% +$1.76M 0.01% 980
2025
Q3
$766K Buy
+25,025
New +$574K ﹤0.01% 1661
2025
Q2
Sell
-43,211
Closed -$803K 2553
2025
Q1
$803K Buy
+43,211
New +$721K 0.01% 1222
2024
Q4
Sell
-8,210
Closed -$275K 2389
2024
Q3
$275K Buy
+8,210
New +$280K ﹤0.01% 1837
2024
Q1
Sell
-75,633
Closed -$1.62M 2265
2023
Q4
$1.62M Buy
+75,633
New +$1.3M 0.01% 750
2023
Q1
Sell
-13,013
Closed -$403K 2454
2022
Q4
$403K Buy
+13,013
New +$368K 0.01% 1565
2022
Q3
Sell
-45,932
Closed -$932K 2751
2022
Q2
$932K Buy
+45,932
New +$1.02M 0.01% 1008
2022
Q1
Sell
-6,643
Closed -$230K 3046
2021
Q4
$230K Sell
6,643
-25,082
-79% -$795K ﹤0.01% 2441
2021
Q3
$860K Sell
31,725
-54,990
-63% -$1.4M 0.01% 1460
2021
Q2
$2.25M Buy
+86,715
New +$2.08M 0.02% 569
2020
Q4
Sell
-22,745
Closed -$335K 1811
2020
Q3
$335K Buy
22,745
+8,697
+62% +$157K 0.01% 1079
2020
Q2
$313K Buy
+14,048
New +$257K 0.01% 971

Other funds holding ANAB

HRT Financial's ANAB Position: Q1 2026 in Review

HRT Financial reduced its AnaptysBio (ANAB) stake by 42% in Q1 2026, selling an estimated $1.59M and leaving 40,504 shares worth $2.25M. The position accounts for 0.01% of the portfolio, ranked #1542.

HRT Financial first reported a position in ANAB in Q2 2020 and has held it in 13 quarters since. The position peaked at $3.4M in Q4 2025. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • HRT Financial held 40,504 shares of AnaptysBio worth $2.25M as of Q1 2026.
  • HRT Financial sold 29,626 AnaptysBio shares in Q1 2026, an estimated $1.59M.
  • AnaptysBio made up 0.01% of HRT Financial's portfolio in Q1 2026, its #1542 holding.
  • HRT Financial first reported a position in AnaptysBio in Q2 2020 and has held it in 13 quarters since.
  • HRT Financial's AnaptysBio position peaked at $3.4M in Q4 2025.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.